Literature DB >> 15767509

Striational antibodies in myasthenia gravis: reactivity and possible clinical significance.

Fredrik Romi1, Geir Olve Skeie, Nils Erik Gilhus, Johan Arild Aarli.   

Abstract

Myasthenia gravis is an autoimmune disease caused, in most cases, by antibodies attaching to the acetylcholine receptor. Some myasthenia gravis patients have antibodies that bind in a cross-striational pattern to skeletal and heart muscle tissue sections (striational antibodies). These antibodies react with epitopes on the muscle proteins titin and ryanodine receptor, are found mainly in sera of patients with thymoma and late-onset myasthenia gravis, and may correlate with myasthenia gravis severity. Their presence may predict an unsatisfactory outcome after thymectomy. The detection of titin and ryanodine receptor antibodies provides more specific clinical information than the immunofluorescent demonstration of striational antibodies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15767509     DOI: 10.1001/archneur.62.3.442

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  36 in total

1.  Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis.

Authors:  Fredrik Romi; Shigeaki Suzuki; Norihiro Suzuki; Axel Petzold; Gordon T Plant; Nils Erik Gilhus
Journal:  J Neurol       Date:  2011-12-14       Impact factor: 4.849

Review 2.  Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.

Authors:  Jeffrey T Guptill; Madhu Soni; Matthew N Meriggioli
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 3.  Muscle giants: molecular scaffolds in sarcomerogenesis.

Authors:  Aikaterini Kontrogianni-Konstantopoulos; Maegen A Ackermann; Amber L Bowman; Solomon V Yap; Robert J Bloch
Journal:  Physiol Rev       Date:  2009-10       Impact factor: 37.312

Review 4.  Myasthenia gravis - autoantibody characteristics and their implications for therapy.

Authors:  Nils Erik Gilhus; Geir Olve Skeie; Fredrik Romi; Konstantinos Lazaridis; Paraskevi Zisimopoulou; Socrates Tzartos
Journal:  Nat Rev Neurol       Date:  2016-04-22       Impact factor: 42.937

Review 5.  Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status.

Authors:  Grayson Beecher; Brendan Nicholas Putko; Amanda Nicole Wagner; Zaeem Azfer Siddiqi
Journal:  Drugs       Date:  2019-03       Impact factor: 9.546

Review 6.  [Myasthenia gravis].

Authors:  Wolfgang Müllges; Guido Stoll
Journal:  Nervenarzt       Date:  2019-10       Impact factor: 1.214

Review 7.  Myasthenia gravis: past, present, and future.

Authors:  Bianca M Conti-Fine; Monica Milani; Henry J Kaminski
Journal:  J Clin Invest       Date:  2006-11       Impact factor: 14.808

Review 8.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

Review 9.  Paraneoplastic neurological syndromes.

Authors:  F Leypoldt; K-P Wandinger
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

10.  Autoantibodies in neuromuscular transmission disorders.

Authors:  Angela Vincent
Journal:  Ann Indian Acad Neurol       Date:  2008-07       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.